<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has informed the BSE that it does not qualify as a 'Large Corporate' under the SEBI framework (Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018) as of March 31, 2025. Because its outstanding borrowings fall below the threshold required for that classification, the company is not required to file the annual disclosure under Annexure B2. Instead, it has submitted Annexure A confirming its non-applicable status. Credit rating and stock exchange fine details are marked as 'NA' since the framework does not apply. The filing has been signed by the Company Secretary and Chief Financial Officer on April 21, 2025.
This is a routine regulatory compliance filing with no material impact on shareholders or the stock price. It simply confirms that Sandu Pharmaceuticals' borrowings are below SEBI's Large Corporate threshold, meaning fewer disclosure obligations.